Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2005

View Archived Issues

Hepatitis B virus responses maintained with long-term adefovir therapy

Good PK and safety profile reported for AMG-162 in healthy men

Etanercept reported to reduce bone resorption in psoriatic arthritis

New data on the potential of ferumoxytol as iron replacement therapy

Atheroprotective effects reported for AST-120 in chronic renal failure patients

GCS-100 induces apoptosis in B-cell malignancies

CpG-7909 increases response to first-line chemotherapy in advanced NSCLC

GSK: five vaccine launches in next five years

Organon and Cypress Bioscience partner in obstructive sleep apnea

Rapid enrollment in ragweed allergy study of AIC

Phase II study evaluates picoplatin for small cell lung cancer

Second phase II trial for Hematide in chronic kidney disease patients

Phase I trial for Hsp90 inhibitor IPI-504

rIL-7 studied in HIV in two new phase I studies

OxThera created to advance Q-Med's oxalate project

Positive antitumor efficacy for MMI-166 in a model of lung cancer

Gefitinib/rosiglitazone combination enhances antiproliferative effects in lung cancer cells

Enrollment completed in phase I/II study of smallpox vaccine candidate LC16m8

A novel ORL1 agonist demonstrates efficacy in a model of neuropathic pain

Solvay signs final purchase agreement for Fournier

Arixtra approved in E.U. for prevention of VTE events in abdominal surgery

CE Mark approval for Axxion drug-eluting stent

Fast track status for Fluviral

Drug discovery targets for diabetes

HIV replication inhibitors from Janssen

Cysteine protease inhibitors in early development at Celera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...